scholarly journals Association of Hepatocyte Growth Factor Genetic Variation (S3735520) and Its Concentration in Autism Spectrum Disorders: A Case-control Study

2020 ◽  
Vol 6 (4) ◽  
pp. 197-204
Author(s):  
Masoumeh Khalili ◽  
◽  
Farhad Mashayekhi ◽  
Zivar Salehi ◽  
◽  
...  
Keyword(s):  
Growth Factor ◽  
Gene Polymorphism ◽  
Hepatocyte Growth Factor ◽  
Serum Levels ◽  
Autism Spectrum ◽  
Enzyme Linked Immunosorbent Assay ◽  
Chi Square ◽  
Genotype Frequencies ◽  
Chi Square Test ◽  
Hepatocyte Growth

Background: Hepatocyte Growth Factor (HGF) was shown to play a key role in synaptogenesis, survival, maturation, and reconstruction of neuron cells and was shown to be implicated in Autism Spectrum Disorder (ASD). Objectives: Assessing the relationship between HGF (rs3735520) gene polymorphism and its circulating levels in ASD. Materials & Methods: A total of 140 ASD patients and 120 children healthy controls referred to Shahid Rajaei Hospital, Mazandaran, Iran from September 2017 to January 2019 were enrolled in the study. Genomic DNA was extracted from blood samples, HGF polymorphism was determined by polymerase chain reaction-restriction fragment length polymorphism and HGF serum concentration was measured by enzyme-linked immunosorbent assay. Statistical analysis was done by ANOVA and the Chi-square test, using χ² in MedCalc statistical software ver. 12.1.4. Results: Genotype frequencies of CC, CT, and TT in the ASD group were 25.71%, 52.86%, and 21.43%, and in controls were 26.67%, 68.33%, and 5%, respectively (P=0003) and C and T alleles frequencies in patients were 53% and 47% and in controls were 61% and 39%, respectively (P=0.046). Moreover, the Mean±SD serum HGF levels in the controls and ASD patients were 363.33±118.44 and 219.95±73.61 pg/mL, respectively (P=0.009). Furthermore, ASD patients carrying TT genotype had lower serum HGF levels than CT and TT carriers (CC, CT, and TT Mean±SD serum levels were 271.88±30.47, 217.77±33.59 and 156.33±22.72 pg/mL, respectively). Conclusion: There was a significant relationship between HGF gene polymorphism and its serum levels with ASD in an Iranian population. We also suggest that TT genotype may be associated with a decrease in HGF circulation levels in ASD.

scholarly journals Analysis of Soluble Mesenchymal-Epithelial Transition Factor and Hepatocyte Growth Factor Serum Levels in Children With Autism Spectrum Disorder

2022 ◽  
Vol 8 (1) ◽  
pp. 26-32
Author(s):  
Somayeh Shabani ◽  
◽  
Soheila Talesh Sasani ◽  
Farhad Mashayekhi ◽  
◽  
...  
Keyword(s):  
Growth Factor ◽  
Hepatocyte Growth Factor ◽  
Serum Levels ◽  
Autism Spectrum ◽  
Vital Role ◽  
Serum Concentrations ◽  
Neurology Clinic ◽  
The Mean ◽  
Mesenchymal Epithelial Transition Factor ◽  
Hepatocyte Growth

Background: Hepatocyte Growth Factor (HGF) and its receptor, Mesothelial-Epithelial Transition (cMet) factor signaling, play an essential role in controlling synaptogenesis. Objectives: Because of the vital role of HGF and Met signaling in synaptogenesis and spatial learning function of the brain’s hippocampal region, we aimed to study the HGF and soluble cMet (s-cMet) serum levels in children with different stages of Autism Spectrum Disorders (ASD). Materials & Methods: A total of 189 ASD patients (mild; n=69, moderate; n=63 and severe; n=57) and 82 control were enrolled in this project. Blood samples were collected from ASD patients referred to Pediatric Neurology Clinic, 17 Shahrivar Hospital, Rasht City, Iran, and serum concentrations of s-cMet and HGF were measured by ELISA. The control children with no clinical characteristics of ASD attended routine blood tests. Results: HGF Mean±SD serum concentration in ASD patients was 239±52.02 pg/mL compared to controls which was 360.04±71.15 pg/mL (P=0.004). Also, the Mean±SD serum concentrations of HGF in mild, moderate, and severe ASD patients were 297.54±69.82, 232.81±56.41, and 189±33.25 ng/mL, respectively, compared to control, which was 360.18±57.40. Besides, the s-cMet Mean±SD serum concentrations in ASD and controls were 143.54±32.50 and 200.25±31.16 pg/mL, respectively (P=0.005). The Mean±SD serum concentrations of s-cMet in the mild, moderate, and severe ASD patients were 172.81±37.69, 129.81±45.55, and 85.18±22.95 ng/mL, respectively, as compared to the control, which was 214.54±34.17 ng/mL. Conclusion: Serum HGF and s-cMet concentration decreased in ASD patients corresponding to disease severity. Also, detecting serum HGF and s-cMet may help classify ASD.

Prognostic Significance of Plasma Hepatocyte Growth Factor in Sepsis

2021 ◽  
pp. 088506662199342
Author(s):  
Fei Peng ◽  
Chenglong Liang ◽  
Wei Chang ◽  
Qin Sun ◽  
Jianfeng Xie ◽  
...  
Keyword(s):  
Endothelial Cell ◽  
Growth Factor ◽  
Hepatocyte Growth Factor ◽  
Cell Injury ◽  
Prognostic Significance ◽  
Trial Registration ◽  
Enzyme Linked Immunosorbent Assay ◽  
Pulmonary Vascular Permeability ◽  
Endothelial Cell Injury ◽  
Hepatocyte Growth

Background: To assess any correlation of plasma hepatocyte growth factor (HGF) levels with relevant endothelial cell injury parameters and determine the prognostic value in septic patients. Methods: A prospective, observational study was conducted in patients with sepsis admitted to the Department of Critical Care Medicine at the Zhongda Hospital from November 2017 to March 2018. Plasma HGF levels were measured by enzyme-linked immunosorbent assay in the first 24 h after admission (day 1) and on day 3. The primary endpoint was defined as all-cause 28-day mortality. Furthermore, we analyzed the correlation of HGF with relevant endothelial cell injury markers. Results: Eighty-six patients admitted with sepsis were included. HGF levels of nonsurvivors were elevated compared to those of survivors on day 1 (1940.62 ± 74.66 pg/mL vs. 1635.61 ± 47.49 pg/mL; P = 0.002) and day 3 (1824.82 ± 137.52 pg/mL vs. 1309.77 ± 83.49 pg/mL; P = 0.001) and showed a strong correlation with von Willebrand factor (r = 0.45, P < 0.0001), lactate (r = 0.35, P = 0.0011), pulmonary vascular permeability index (r = 0.38, P = 0.0241), first 24 h fluid administration (r = 0.38, P < 0.0001), and sequential organ failure assessment score (r = 0.40, P = 0.0001). Plasma HGF levels were able to prognostically discriminate between survivors and nonsurvivors on day 1 (AUC: 0.72, 95%CI: 0.60-0.84) and day 3 (AUC: 0.77, 95%CI: 0.63-0.91). Conclusions: HGF levels are associated with sepsis and correlated with established markers of endothelial cell injury. Elevated HGF levels in sepsis patients are an efficient indicator of poor prognosis. Trial registration: The study was registered in Clinical Trial (Registration Number: NCT02883231).

scholarly journals Decreased Serum Hepatocyte Growth Factor (HGF) in Autistic Children with severe Gastrointestinal Disease

2009 ◽  
Vol 4 ◽  
pp. BMI.S3656 ◽  
Author(s):  
A.J. Russo ◽  
A. Krigsman ◽  
B. Jepson ◽  
Andrew Wakefield
Keyword(s):  
Growth Factor ◽  
Hepatocyte Growth Factor ◽  
Gastrointestinal Disease ◽  
Serum Levels ◽  
Autistic Children ◽  
Functional Connection ◽  
Disease Symptoms ◽  
Lymphoid Nodular Hyperplasia ◽  
Lymphoid Nodules ◽  
Hepatocyte Growth

Aim To assess serum Hepatocyte Growth Factor (HGF) levels in autistic children with severe gastrointestinal (GI) disease and to test the hypothesis that there is a relationship between GI pathology and HGF concentration. Subjects and Methods Serum from 29 autistic children with chronic digestive disease (symptoms for a minimum of 6–12 months), most with ileo-colonic lymphoid nodular hyperplasia (LNH—markedly enlarged lymphoid nodules) and inflammation of the colorectum, small bowel and/or stomach), and 31 controls (11 age matched autistic children with no GI disease, 11 age matched non autistic children without GI disease and 9 age matched non autistic children with GI disease) were tested for HGF using ELISAs. HGF concentration of autistic children with GI disease was compared to GI disease severity. Results Autistic children with GI disease had significantly lower serum levels of HGF compared to controls (autistic without GI disease; p = 0.0005, non autistic with no GI disease; p = 0.0001, and non autistic with GI disease; p = 0.001). Collectively, all autistic children had significantly lower HGF levels when compared to non autistic children (p < 0.0001). We did not find any relationship between severity of GI disease and HGF concentration in autistic children with GI disease. Discussion These results suggest an association between HGF serum levels and the presence of GI disease in autistic children and explain a potential functional connection between the Met gene and autism. The concentration of serum HGF may be a useful biomarker for autistic children, especially those with severe GI disease.

Induction of liver growth in normal mice by infusion of hepatocyte growth factor/scatter factor

1995 ◽  
Vol 268 (2) ◽  
pp. G380-G386 ◽  
Author(s):  
F. Roos ◽  
A. M. Ryan ◽  
S. M. Chamow ◽  
G. L. Bennett ◽  
R. H. Schwall
Keyword(s):  
Growth Factor ◽  
Hepatocyte Growth Factor ◽  
Dextran Sulfate ◽  
Plasma Concentrations ◽  
Elevated Serum ◽  
Serum Levels ◽  
Serum Biochemistry ◽  
Scatter Factor ◽  
Liver Growth ◽  
Hepatocyte Growth

Hepatocyte growth factor/scatter factor (HGF/SF) is a potent stimulator of DNA synthesis in a variety of epithelial cells, including hepatocytes, and has been implicated in liver regeneration. We show here that combining dextran sulfate with HGF/SF markedly increases the plasma concentrations of HGF/SF that are achieved during intraperitoneal infusion. Three days of administration of HGF/SF by this mechanism caused a dose-dependent increase in liver wet weight. Mitotic figures were rarely observed in control livers but were abundant in livers exposed to HGF/SF, and liver DNA content was elevated. Serum levels of triglycerides, cholesterol, total protein, and albumin were also dose dependently increased, whereas alkaline phosphatase was reduced. From these data we conclude 1) that combining HGF/SF with dextran sulfate provides a novel method for delivering HGF/SF in a continuous manner, 2) that HGF/SF can induce liver growth in an intact animal, and 3) that HGF/SF-induced liver enlargement is associated with changes in serum biochemistry.

Serum Levels of Hepatocyte Growth Factor/Scatter Factor in Patients with Liver Metastases from Breast Cancer

Tumor Biology ◽  
2007 ◽  
Vol 28 (1) ◽  
pp. 36-44 ◽  
Author(s):  
Michael H.R. Eichbaum ◽  
Thomas M. de Rossi ◽  
Sepp Kaul ◽  
Thomas Bruckner ◽  
Andreas Schneeweiss ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Growth Factor ◽  
Hepatocyte Growth Factor ◽  
Liver Metastases ◽  
Serum Levels ◽  
Scatter Factor ◽  
Hepatocyte Growth

scholarly journals Decreased Serum Hepatocyte Growth Factor (HGF) in Individuals with Depression Correlates with Severity of Disease

2010 ◽  
Vol 5 ◽  
pp. BMI.S5183 ◽  
Author(s):  
A.J. Russo
Keyword(s):  
Growth Factor ◽  
Hepatocyte Growth Factor ◽  
Disease Severity ◽  
Serum Levels ◽  
Lower Serum ◽  
Severity Of Disease ◽  
Clinically Depressed ◽  
Severity Of Depression ◽  
Predictive Strength ◽  
Hepatocyte Growth

Aim To assess serum Hepatocyte Growth Factor (HGF) levels in individuals with depression and to test the hypothesis that there is a relationship between severity of depression and HGF concentration. Subjects and methods Serum from 26 clinically depressed individuals and 19 controls were tested for serum HGF using ELISAs. Correlation was established between HGF concentration and disease severity. Results Depressed individuals had significantly lower serum levels of HGF compared to controls ( P < 0.0001). HGF concentration correlated with overall depressive behavior ( P = 0.03) and specifically depression ( P = 0.02), but not anxiety ( P = 0.36). Discussion These results suggest an association between HGF serum levels and clinically depressed individuals and demonstrate a correlation between severity of depression and HGF levels. Further studies of the predictive strength of HGF as a biomarker for depression may be warranted.

The low levels of circulating hepatocyte growth factor in nephrolithiasis cases: independent from gene polymorphism

Urolithiasis ◽  
2015 ◽  
Vol 43 (5) ◽  
pp. 427-432
Author(s):  
Nurinnisa Ozturk ◽  
Hulya Aksoy ◽  
Yilmaz Aksoy ◽  
Abdulkadir Yildirim ◽  
Fatih Akcay ◽  
...  
Keyword(s):  
Growth Factor ◽  
Gene Polymorphism ◽  
Hepatocyte Growth Factor ◽  
Low Levels ◽  
Hepatocyte Growth

Increased Levels of Hepatocyte Growth Factor in Patients with DIC.

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 1041-1041
Author(s):  
Kazuo Kawasugi ◽  
Maho Noguchi ◽  
Haruko Tashiro ◽  
Moritaka Gotoh ◽  
Naoki Shirafuji ◽  
...  
Keyword(s):  
Growth Factor ◽  
Hepatocyte Growth Factor ◽  
Plasma Levels ◽  
Enzyme Linked Immunosorbent Assay ◽  
Specific Growth Factor ◽  
One Step ◽  
Sandwich Enzyme Immunoassay ◽  
The Relationship ◽  
Hepatocyte Growth

Abstract Injury of endothelial cells has been postulated as an initial trigger of the progression of DIC. Although hepatocyte growth factor (HGF) is a member of endothelium-specific growth factor, the relationship between HGF and DIC has not been described. To investigate the role of HGF, we measured plasma levels of HGF in patients with sepsis-associated (n=20) and acute promyelocytic leukemia (APL)-induced DIC (n=6). Plasma samples from those patients groups were assayed for HGF levels by enzyme-linked immunosorbent assay (ELIZA, TECHNE Corporation, USA). The VEGF levels were determined by one-step sandwich enzyme immunoassay (EIA, Chemicon International, USA). The thrombin antithrombin complexes (TAT) levels were higher in both DIC patients as reported by others. In the septic patients with DIC, we found significant elevations in HGF levels compared to normal controls. Also, the HGF levels were elevated in the APL patients with DIC. However, we did not find any difference in plasma levels of VEGF in the APL and septic patients with DIC. There was a slight correlation between the TAT and HGF levels in both (septic and APL) patients groups with DIC. These results suggest that plasma levels of HGF may be candidates for a marker of DIC. It appears that HGF may contribute to the severity of DIC. Sepsis associated DIC APL with DIC Controls (n=10) *(P<0.005) significantly different controls HGF 7949±71230* 11902±10726 846±216pg/ml VEGF 172±7.0 209±35 188±8pg/ml TAT 28.4±17.5* 22.5±15.3* <3 μg/ml

Hepatocyte Growth Factor and its Receptor C-Met in Rat and Rabbit Vocal Folds

2002 ◽  
Vol 111 (8) ◽  
pp. 661-666 ◽  
Author(s):  
Shigeru Hirano ◽  
Susan Thibeault ◽  
Charles N. Ford ◽  
Diane M. Bless ◽  
Shin-Ichi Kanemaru
Keyword(s):  
Wound Healing ◽  
Growth Factor ◽  
Hepatocyte Growth Factor ◽  
Lamina Propria ◽  
Vocal Fold ◽  
Vocal Folds ◽  
Enzyme Linked Immunosorbent Assay ◽  
Alternative Approach ◽  
Fibrotic Scar ◽  
Hepatocyte Growth

Vocal fold fibrotic scar is characterized by fibrosis of the lamina propria and epithelium, and is difficult to treat. Hepatocyte growth factor (HGF) has antifibrotic activity and has received attention as a possible therapeutic alternative to treat fibrosis. In this study, in order to clarify whether HGF can be involved in vocal fold scarring, we examined the existence of HGF and its receptor, c-Met, in rat vocal folds, and then the activity of HGF in rabbit injured vocal folds, using immunohistochemistry and enzyme-linked immunosorbent assay. We found HGF and c-Met on epithelial cells and gland cells of the rat vocal folds. On the injured vocal folds of rabbits, little HGF was observed immediately after injury, but prominent activity occurred simultaneously with reepithelialization of the vocal fold mucosa on days 10 to 15. The activity of HGF was observed on fibroblasts in the lamina propria, as well as the epithelium. It is suggested that HGF in the vocal folds is produced by the fibroblasts and delivered to the epithelium. The implication of these findings is that HGF is involved in wound healing of the vocal fold, and may provide an alternative approach in preventing and treating vocal fold scarring.

scholarly journals PRLR-AluI Gene Polymorphism And Litter Size Traits In Highly Prolific Line Of Topigs 20 Sows

2015 ◽  
Vol 65 (4) ◽  
pp. 463-476 ◽  
Author(s):  
Sven Menčik ◽  
Vlado Vuković ◽  
Mario Modrić ◽  
Marija Špehar ◽  
Mario Ostović ◽  
...  
Keyword(s):  
Gene Polymorphism ◽  
Litter Size ◽  
Prolactin Receptor ◽  
Calculation Model ◽  
Chi Square ◽  
Test Analysis ◽  
Genotype Frequencies ◽  
Chi Square Test ◽  
Hardy Weinberg Equilibrium ◽  
The Difference

AbstractThe objective of the present study was to identify the Prolactin Receptor (PRLR) gene polymorphism related to litter size traits. The study included 101 Topigs 20 line of sows with 426 litters. The traits studied were: Total Number of Born (TNB), Number of Born Alive (NBA), Number of Still Born (NSB), and Number of MUMmified (NMUM) piglets. Polymorphism was identified with the polymerase chain reaction-restriction fragment length polymorphism method. Allelic and genotype frequencies and deviation from Hardy-Weinberg equilibrium were verified with the chi-square test. Analysis of litter size traits was performed using the General Linear Model, which included the potential environmental effects. Additive and dominant allele variances were observed by the regression procedure. In the studied population of sows, the frequency of heterozygotes (0.5149) for PRLR gene exceeded the total number of AA (0.0198) and BB (0.4653) homozygotes, which resulted in a high proportion of B allele (0.7228). The results for PRLR showed statistically significant (P<0.05) differences in first parity sows between BB and AB genotypes for TNB and NBA. Significant differences(P<0.05) were recorded in third parity sows between BB and AB genotypes for NBA, and in AA genotypeversusAB and BB genotypes for NMUM. The fourth and subsequent parity sows of AA genotype had a significantly higher (P<0.05) rate of NBA as compared with those of AB and BB genotypes. In all parities analysed, the difference between the BB and AB genotypes for NBA was statistically significant (P<0.05). Interpretation of the results at the levels of phenotypes and either additive or dominant variance was quite difficult due to the small number of AA homozygous sows. The calculation model yielded a significant effect (P<0.05) as well as tendency (P<0.1) for the mentioned effects except for age at first farrowing.

Sign in / Sign up

Export Citation Format

Share Document